Secondary rhegmatogenous retinal detachment following intravitreal bevacizumab in patients with vitreous hemorrhage or tractional retinal detachment secondary to Eales' disease

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 250, Issue 5, 2012, Pages 685-690

  Kumar, Atul ^a   Sehra, Sri Vatsa ^a   Thirumalesh, M B ^a   Gogia, Varun ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Eales' disease; Intravitreal bevacizumab; Pars plana vitrectomy; Rhegmatogenous retinal detachment

Indexed keywords

BEVACIZUMAB;

ADULT; ARTICLE; CASE STUDY; CLINICAL ARTICLE; COMPARATIVE STUDY; DISEASE ASSOCIATION; DRUG ADMINISTRATION ROUTE; DRUG SAFETY; EALES DISEASE; HUMAN; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RETINA DETACHMENT; RETROSPECTIVE STUDY; TREATMENT DURATION; VISUAL ACUITY; VITRECTOMY; VITREOUS BODY DETACHMENT; VITREOUS HEMORRHAGE;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; INTRAVITREAL INJECTIONS; MALE; NEOVASCULARIZATION, PATHOLOGIC; RECURRENCE; RETINAL DETACHMENT; RETINAL VASCULITIS; RETROSPECTIVE STUDIES; VISUAL ACUITY; VITRECTOMY; VITREOUS HEMORRHAGE; YOUNG ADULT;

EID: 84862840064     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-011-1890-7     Document Type: Article

References (23)

1. Atmaca LS, Nagpal PN (1998) Eales' disease: medical, laser, and surgical treatments. Ophthalmol Clin North Am 11 (4): 619-626
2. Das T, Biswas J, Kumar A, Nagpal PN, Namperumalsamy P, Patnaik B, Tewari HK (1994) Eales' disease. Indian J Ophthalmol 42 (1): 3-18
3. Eales H (1882) Primary retinal haemorrhage in young men. Ophthalmic Rev 1: 41-46
4. Patnaik B, Nagpal PN, Namperumalsamy P, Kalsi R (1998) Eales' disease: clinical features, pathophysiology, etiopathogenesis. Ophthalmol Clin North Am 11 (4): 601-617
5. Biswas J, Sharma T, Gopal L, Madhavan HN, Sulochana KN, Ramakrishnan S (2002) Eales disease-an update. Surv Ophthalmol 47 (3): 197-214
6. Kumar A, Tiwari HK, Singh RP, Verma L, Prasad N (2000) Comparative evaluation of early vs deferred vitrectomy in Eales' disease. Acta Ophthalmol Scand 78 (1): 77-78
7. Shanmugam MP, Badrinath SS, Gopal L, Sharma T (1998) Long term visual results of vitrectomy for Eales' disease complications. Int Ophthalmol 22 (1): 61-64
8. Shukla D, Kanungo S, Prasad NM, Kim R (2007) Surgical outcomes for vitrectomy in Eales' disease. Eye 22 (7): 900-904
9. El-Asrar AM, Al-Kharashi SA (2002) Full panretinal photocoagulation and early vitrectomy improve prognosis of retinal vasculitis associated with tuberculoprotein hypersensitivity (Eales' disease). Br J Ophthalmol 86 (11): 1248
10. Perentes Y, Chan CC, Bovey E, Uffer S, Herbort CP (2002) Massive vascular endothelium growth factor (VEGF) expression in Eales' disease [Massive Expression von vascular Endothelium Growth Factor (VEGF) in einem Fall von Eales' Krankheit]. Klin Monatsbl Augenheilkd 219: 311-314
11. Kumar A, Sinha S (2007) Rapid regression of disc and retinal neovascularization in a case of Eales disease after intravitreal bevacizumab. Can J Ophthalmol 42 (2): 335-336
12. Küçükerdönmez C, Akova YA, Yilmaz G (2008) Intravitreal injection of bevacizumab in Eales' disease. Ocul Immunol Inflamm 16 (1-2): 63-65
13. Chanana B, Azad RV, Patwardhan S (2010) Role of intravitreal bevacizumab in the management of Eales' disease. Int Ophthalmol 30 (1): 57-61
14. Raju B, Raju NSD, Raju AS, Rajamma SP (2009) Spontaneous relief of vitreomacular traction and regression of neovascularization in Eales' disease after intravitreal injection of bevacizumab. Retinal Cases Brief Rep 3 (2): 128-129
15. Patwardhan SD, Azad R, Shah BM, Sharma Y (2011) Role of intravitreal bevacizumab in Eales' disease with dense vitreous hemorrhage: a prospective randomized control study. Retina 31 (5): 866-870
16. Spaide RF, Fisher YL (2006) Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26 (3): 275
17. Adamis AP, Altaweel M, Bressler NM, Cunningham ET Jr, Davis MD, Goldbaum M, Guyer DR, Barrett K (2006) Patel M (2006) Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 113 (1): 23
18. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ, Wendel R, Patel A (2006) Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113 (10): 1695-1705
19. Chen E, Park CH (2006) Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina 26 (6): 699
20. Arevalo JF, Maia M, Flynn HW, Saravia M, Avery RL, Wu L, Farah ME, Pieramici DJ, Berrocal MH, Sanchez JG (2008) Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 92 (2): 213
21. Abdelhakim MASE, Macky TA, Mansour KAG, Mortada HA (2011) Bevacizumab (Avastin) as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series. Ophthalmic Res 45 (1): 23-30
22. Cheema RA, Mushtaq J, Al-Khars W, Al-Askar E, Cheema MA (2010) Role of intravitreal bevacizumab (Avastin) injected at the end of diabetic vitrectomy in preventing postoperative recurrent vitreous hemorrhage. Retina 30 (10): 1646
23. Sigelman J, Ozanics V (1982) Retina. In: Jakobiec FA (ed) Ocular anatomy, embryology and teratology. Harper and Rowe, Philadelphia, pp 456-459